Potential conflict of interest: Dr. Bruix is a consultant for, advises, is on the speakers' bureau of, and received grants from Bayer. He is a consultant for and advises Bristol-Myers Squibb. He is also a consultant for Biocompatibles, GlaxoSmithKline, Kowa, Novartis, and ArQule.‡
This work was supported a grant from Instituto de Salud Carlos III (PI08/0146). CIBERehd is funded by Instituto de Salud Carlos III. M.R. was supported by a grant from the University of Barcelona (APIF RD63/2006).